SCHEMBL3717372

SCHEMBL3717372

COc1ccc(Cn2ncc3c(O)c(Cl)cnc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPT P10636 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
NPBWR1 P48145 10/20 0.51
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MCHR1 Q99705 1/20 0.47
PDE1A P54750 3/20 0.44
PDE1B Q01064 3/20 0.44
PDE1C Q14123 3/20 0.44
CNR2 P34972 1/20 0.43
PKM P14618 1/20 0.43
PKLR P30613 1/20 0.43
ACVR1B P36896 1/20 0.42
TGFBR1 P36897 1/20 0.42
ACVRL1 P37023 1/20 0.42
ACVR1 Q04771 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3724625 0.86 LMNA (0.51) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL3722773 0.86 LMNA (0.51) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL20176618 0.85 LMNA (0.52) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL2792459 0.83 ALDH1A1 (0.49) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL30644829 0.83 ALDH1A1 (0.49) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL25280498 0.83 LMNA (0.48) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL31140644 0.83 LMNA (0.48) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL1943995 0.82 LMNA (0.54) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL1944851 0.81 LMNA (0.53) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1
SCHEMBL15555752 0.80 LMNA (0.52) LMNAALDH1A1MAPTSMN1; SMN2NPBWR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8372842-B2 Pyrazolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-02-12 US disclosed
EP-2242757-B1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2012-08-01 EP disclosed
US-20100280043-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2010-11-04 US disclosed
EP-2242757-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-27 EP disclosed
WO-2009089359-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100280043-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B LMNA 1369/4885ALDH1A1 2032/4885MAPT 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.